Back

Inhibition of fractalkine signalling in patients with acute myocardial infarction - First results from the FRACTAL trial

2 September 2024 (12:00 - 12:12)
Organised by: Logo
Congress Presentation Part of: Therapeutic targets for myocardial infarction Leukocytes, Inflammation, Immunity ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Ioakim Spyridopoulos

Newcastle University, Newcastle-Upon-Tyne (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
From bench to bedside and back to bench: investigating the role of platelet heterogeneity in coronary artery disease
Doctor D. Bongiovanni (Augsburg, DE)
Abstract Slides Video
Presentation thumbnail
Downregulation of CPEB3 exacerbates cardiac injury by inhibiting cardiomyocyte adaptive metabolic reprogramming after myocardial infarction
Doctor Z. Tao (Nanjing, CN)
Abstract Slides Video
Presentation thumbnail
Lipin1 prevents ischemic heart disease by regulating lipid homeostasis
Doctor J. Guo (Hangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Oxct1 regulates cardiomyocyte PANoptosis in acute myocardial infarction via succinylating Tfam
Miss X. Li (Nanjing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Therapeutic targets for myocardial infarction
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Fractalkine Inhibition in Acute Myocardial Infarction leads to reduced intramyocardial haemorrhage
thumbnail
Congress Session
Novel pharmacological approaches in acute coronary syndromes
thumbnail
Congress Presentation
Effect of pre-hospital pulse-dose glucocorticoid on infarct size in st-segment elevation myocardial infarction: a randomized, blinded, placebo-controlled clinical trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources